Trials Searches
- Obesity
- Leukemia
- Healthy
- Diabetic Neuropathies
- Gastrointestinal Diseases
- HIV Infections
- Newly Diagnosed Cancer Patients
- Spinal Muscular Atrophy Type I
- Ovarian Stimulation
- Healthy Students
- Violence
- Non-cancer Affected Volunteers
- Breast Cancer
- Non Resectable Metastasis
- Bladder, Neurogenic
- Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
- Nephrosis
- Locally Advanced Non Small-Cell Lung Canger
- Alpha-1 Antitrypsin Deficiency
- Non-melanoma Skin Cancer
- Neisseria Gonorrhoeae
- Urolithiasis
- Dyslexia
- Non-cancer Pain
- Acral Melanoma
Upper Limit of Leucine Intake in Adults
Overview:
Study State Date: May 2009
Primary Completion Date: Anticipated January 2010
Study Type: Interventional
Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject)
Phase: Phase 1
Trial Identifier: NCT00972582
Official Title: Determination of the Tolerable Upper Limit of Leucine Intake in Adult Humans
Description: When dietary amino acid supplements are consumed by humans they are normally in addition to their normal daily requirements. The investigators' laboratory played a leading role in defining the estimated average requirement (EAR) and the recommended dietary intake for the "essential" amino acids (Dietary Reference Intakes 2005). The other important but less well studied component of Dietary Reference Intakes (DRI) is - What is a safe upper limit of intake? The investigators now propose to determine the safe upper limits of the dietary essential amino acids. The recently published DRI (2005) defines the Tolerable Upper Intake Level (UL) as 'the highest average daily nutrient intake level that is likely to pose no risk of adverse health effects to almost all individuals in the general population.' As intake increases above the UL, the potential risk of adverse effects may increase'. In this proposal, the investigators define a novel method to define the safe upper limit where the 'maximum oxidative potential' of an amino acid identifies the 'metabolic limit' to dispose the amino acid. Intakes of amino acid above this level will increase the potential for adverse effects to appear.
+ Additional Objectives Detail
The objective of the study will be to determine the 'metabolic limit' of leucine oxidation in healthy young men by: A) Measuring leucine oxidation in response to short term (8 hr) graded excess leucine intake B) Correlating changes in leucine oxidation with changes in plasma concentrations of keto-isocaproic acid (KIC, the first breakdown product of leucine metabolism), other essential amino acids, ammonia, urea, creatinine, glucose, insulin, and electrolytes (sodium, potassium, chloride) to identify potential biomarkers C) Correlating changes in leucine oxidation with changes in urinary excretion of leucine and ketoisocaproic acid (KIC), urea and creatinine to identify potential biomarkers
Eligibility:
Accepts Healthy Volunteers?: Accepts Healthy VolunteersEnrollment: 10 Anticipated
Minimum Age: 18 Years
Maximum Age: 35 Years
Gender(s): Male
Additional Criteria: Inclusion Criteria: - Male - 18-35 years old Exclusion Criteria: - Report a recent history of sudden weight loss - Have unusual dietary habits such as chronic consumption of caffeinated beverages or alcohol - Have any endocrine disorders - Are currently using any prescribed medications
Healthy
Dietary Supplement: Leucine Increase
Time Frame: Study Visits 1-7 (-45min,-30min,-15min, +2.5hrs, +3hrs, +3.5Hrs +4hrs)
Safety Issue: No
Time Frame: Study Visits 1-7 (Hourly)
Safety Issue: No
Urine
Time Frame: Study Visits 1-7 (8hr timepoint)
Safety Issue: No
VCO2
Time Frame: Study Visits 1-7 (after 5hr meal)
Safety Issue: No
Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
Location & Contacts:
Contacts:Rajavel Elango, PhD (416) 813-7654x6175 rajavel.elango@sickkids.ca
Investigators:
Principal Investigator: Paul B Pencharz, MD, The Hospital for Sick Children, Toronto, Canada
Responsible Party:
The Hospital for Sick Children (Paul Pencharz/Principal Investigator)
Study Locations:
+ Show All 1 Study Locations
Canada
The Hospital for Sick Children (Recruiting)
Toronto, Canada
Trials News
03/14/2010
There are a number of clinical trials underway to find effective treatments for diabetes, including new drugs, surgery and even transplantation.
03/07/2010
There are several current and ongoing trials of interventions for major depressive disorder, which is characterized by a disabling combination of symptoms causing severe disruption to the sufferer's ability to carry out routine functions and tasks of daily life.
02/28/2010
Constipation is a illness where the bowels cannot move waste material out of the body in a normal manner. There are various clinical trials recruiting participants to study the effectiveness of various treatments.
